Emerging Topic Conference 2025: MASLD, MetALD and ALD: Challenges and Opportunities

Topic Theme: MetALD: Challenges and Opportunities Part I

Session 1: Pre-Clinical and/or Translational Data on MetALD

• Introduction
• Animal Models in MetALD: Lessons from MASLD and ALD
  Gyongyi Szabo,MD, PhD, FAASLD
• Genetics in MetALD 
  Timothy Morgan, MD, FAASLD
• Molecular Evidence of MetALD and Common Pathways
  Anna Mae Diehl, MD, FAASLD
• Leveraging Omics for MetALD (Genomics, Transcriptomics, Epigenomics): Biomarkers
  Suthat Liangpunsakul, MD, MPH, AGAF, FAASLD
• Panel Discussion / Q&A
• Break

Session 2: Epidemiology and Population Health

• Refining the Definition of MetALD
  Gene Im, MD, FAASLD
• Epidemiology of MASLD and ALD
  Aleksander Krag, MD, PhD
• What Is the Contribution of Alcohol Consumption to Liver Disease?
  Jurgen Rehm, PhD
• The Role of Public Health Policies in MetALD
  Luis Antonio Diaz
• Panel Discussion / Q&A
• Adjourn

Topic Theme: MetALD: Challenges and Opportunities Part II

Session 3: Diagnosis

• Frontline Strategies for Early Detection of MetALD and ALD (engaging primary care, FIB-4 in EHR, to reduce hepatology burden, etc.)
   Maja Thiele, MD
• Opportunistic Strategies for Diagnosis and Initial Treatment of MetALD and ALD (ED, addiction teams for admitted patients, Fibroscan, AUD treatment)
  Douglas Simonetto, MD
• Patient Preferences and Barriers to Alcohol Diagnosis and Treatment
  Jennifer Jones
• Strategies to Engage Marginalized/Underrepresented Patients with MetALD/ALD: Women, Minorities, Elderly
  Tiffany Wu, MD, MS
• Panel Discussion / Q&A
• Lunch w/optional industry symposium

Session 4: Treatment 

• MASLD Drugs in MetALD (GLP1, vs FGFs, vs SGLT2is)
  Alina Allen, MD
• AUD Medications and Behavioral Interventions in MetALD
  Jessica Mellinger, MD
• Targeting Alcohol Liver Injury in MetALD (Liver Regeneration, Inflammation, Gut-Liver Axis)
  Philippe Mathurin, MD, PhD
• Liver Transplant in MetALD
  Michael Lucey, MD, FAASLD
• Panel Discussion / Q&A
• Lunch w/optional industry symposium

Topic Theme: MASH: The Era of Liver Targeted Therapies, the Intersection with Obesity Medicine and the Evolving Clinical Practice and Trials Landscape Part I

Session 5: MASH Clinical Practice and Trials Landscape in 2025 

• Introduction
• Strategies for Identifying At-Risk Patients, Monitoring Response, and Stopping Rules for Resmetirom
  Meena Bansal, MD, FAASLD
• Updates on MASH Trials: Oral Therapy
  Rohit Loomba, MD, MHSc, FAASLD
• Updates on MASH Trials: Injectable Therapy
  Naim Alkhouri, MD, FAASLD
• Safety and Other Considerations for Current and Future Therapies
  Mary Rinella, MD, FAASLD
• Panel Discussion / Q&A
• Break

Session 6: MASH Clinical Practice & Real World Considerations in 2025 

• Current Use of GLP-1s and Duals in Clinical Practice to Manage T2DM
  Fernando Bril, MD
• Current Use of GLP-1s and Duals in Clinical Practice to Manage Obesity
  Kenneth Cusi, MD, FACP, FACE
• MASH in the Pediatric Population: An Update
  Miriam Vos, MD, MSPH, FAASLD
• Liver Fibrosis, Cardiovascular, or Obesity Outcomes in Clinical Practice: Is There a Hierarchy?
  Zobair Younossi, MD, MPH, FAASLD
• Panel Discussion / Q&A
• Poster Session and Reception

Topic Theme: MASH: The Era of Liver Targeted Therapies, the Intersection with Obesity Medicine and the Evolving Clinical Practice and Trials Landscape Part II

Session 7: MASH Clinical Practice in 2025 (Alternative Approaches to Manage MASH & Obesity)

• Breakfast w/optional industry symposium
• Is Bariatric Surgery Still Relevant in the Management of Obese Patients with MASH?
  Ali Aminian, MD
• Is Endobariatric Treatment Superseded by GLP-1 Agonists, and Can It Be Utilized in MASH Patients in 2025?
  Pichamol "Sigh" Jirapinyo, MD
• How Can I Enhance MASH and Obesity Management in a GI Division?
  W. Ray Kim, MD, FAASLD
• Putting It All Together in Clinical Practice & Research: A Metabolic Institute with Multidisciplinary Management
  Saul Karpen, MD, PhD, FAASLD
• Panel Discussion / Q&A
• Break

Session 8: Endpoints and Clinical Trial Design: Part I 

• Challenges and Opportunities in MASH Trials Post-First FDA Drug Approval: Changes with Resmetirom
  Manal Abdelmalek, MD, MPH, FAASLD
• Encouraging Patient Particiaption in Clinical Trials
  Bilal Hameed, MD, FAASLD
• Summary of MASH Cirrhosis Trials
  Naga Chalasani, MD, FAASLD
• Challenges and Opportunities for Future MASH Combination Trials
  Michael Charlton, MD, FRCP
• Panel Discussion / Q&A
• Lunch w/optional industry symposium

Topic Theme: ALD, MASLD, and MetALD: Bringing it All Together

Session 9: MASH Clinical Practice & Real World Considerations in 2025 

• Introduction
• Lessons Learned from Clinical Trials in MASLD and ALD
  Craig J. McClain, MD, FAASLD
• Designing Clinical Trials for MetALD
  Mazen Noureddin, MD, MHSc
• AUD and Alcohol Endpoints for Clinical Trials in MetALD: Screening of AUD, Pharmacotherapy, Behavioral Therapy
  Ashwani Singal, MD, MS, FACG, FAASLD
• Use of Biomarkers in MetALD (MRI, PEth, NITs): Is Liver Biopsy Still Required?
  Brian Lee, MD
• Panel Discussion / Q&A
• Break

Session 10: Endpoints and Clinical Trial Design: Part II

• Optimizing Recruitment in MetALD Trials
  Norah Terrault, MD, MPH, FAASLD
• Perspective: Government Research Funding Program (NIAAA) 
  Kathy Jung, PhD
• Perspective: Government Research Funding Program (NIDDK) 
  Jay Hoofnagle, MD, FAASLD
• Perspective: Regulatory Agency
  Tram Tran, MD, FAASLD
• Future Directions in MetALD 
  Juan Pablo Arab, MD, FRCPC
• Panel Discussion / Q&A
• Adjourn

Continuing Medical Education (CME)

Accreditation Statement: The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement: AASLD designates this enduring activity for a maximum of 16.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.